Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1983 1
1986 3
1987 5
1988 53
1989 118
1990 106
1991 121
1992 136
1993 161
1994 159
1995 167
1996 139
1997 138
1998 172
1999 160
2000 118
2001 155
2002 171
2003 175
2004 173
2005 214
2006 208
2007 200
2008 208
2009 218
2010 259
2011 252
2012 276
2013 288
2014 330
2015 331
2016 335
2017 360
2018 337
2019 338
2020 375
2021 380
2022 340
2023 299
2024 122

Text availability

Article attribute

Article type

Publication date

Search Results

7,226 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Precursor lymphoblastic lymphoma/leukemia"
Page 1
How I treat relapsed acute lymphoblastic leukemia in the pediatric population.
Hunger SP, Raetz EA. Hunger SP, et al. Blood. 2020 Oct 15;136(16):1803-1812. doi: 10.1182/blood.2019004043. Blood. 2020. PMID: 32589723 Free article. Review.
Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. ...Until recently, treatment options were limited to intensive cytotoxic chemotherapy with …
Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well be …
Lymphoblastic Lymphoma: a Concise Review.
Intermesoli T, Weber A, Leoncin M, Frison L, Skert C, Bassan R. Intermesoli T, et al. Curr Oncol Rep. 2022 Jan;24(1):1-12. doi: 10.1007/s11912-021-01168-x. Epub 2022 Jan 20. Curr Oncol Rep. 2022. PMID: 35059993 Review.
PURPOSE OF REVIEW: Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-Hodgkin lymphoma variant virtually indistinguishable from acute lymphoblastic leukemia (ALL). ...Positron-emission tomography, genetic risk classifications, and min …
PURPOSE OF REVIEW: Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-Hodgkin lymphoma variant virtually ind …
MRD in ALL: Optimization and Innovations.
Pierce E, Mautner B, Mort J, Blewett A, Morris A, Keng M, El Chaer F. Pierce E, et al. Curr Hematol Malig Rep. 2022 Aug;17(4):69-81. doi: 10.1007/s11899-022-00664-6. Epub 2022 May 26. Curr Hematol Malig Rep. 2022. PMID: 35616771 Review.
PURPOSE OF REVIEW: Measurable residual disease (MRD) is an important monitoring parameter that can help predict survival outcomes in acute lymphoblastic leukemia (ALL). Identifying patients with MRD has the potential to decrease the risk of relapse with the i …
PURPOSE OF REVIEW: Measurable residual disease (MRD) is an important monitoring parameter that can help predict survival outcomes in …
Acute Lymphoblastic Leukemia in the Older Adult.
Aldoss I, Forman SJ, Pullarkat V. Aldoss I, et al. J Oncol Pract. 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271. J Oncol Pract. 2019. PMID: 30763199 Review.
Acute lymphoblastic leukemia (ALL) in older adults presents a real challenge as a result of adverse disease biology and comorbidities that preclude delivering curative regimens. ...Immunotherapies such as chimeric antigen receptor-modified T-cells, the bispecific T- …
Acute lymphoblastic leukemia (ALL) in older adults presents a real challenge as a result of adverse disease biology and comorb …
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.
Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit YC, Izraeli S, Yeoh AE, Liang DC, Downing JR, Evans WE, Relling MV, Mullighan CG. Pui CH, et al. J Clin Oncol. 2015 Sep 20;33(27):2938-48. doi: 10.1200/JCO.2014.59.1636. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304874 Free PMC article. Review.
PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performe …
PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia …
Management of Down Syndrome-Associated Leukemias: A Review.
Verma A, Lupo PJ, Shah NN, Hitzler J, Rabin KR. Verma A, et al. JAMA Oncol. 2023 Sep 1;9(9):1283-1290. doi: 10.1001/jamaoncol.2023.2163. JAMA Oncol. 2023. PMID: 37440251 Review.
IMPORTANCE: Down syndrome (DS), caused by an extra copy of material from chromosome 21, is one of the most common genetic conditions. The increased risk of acute leukemia in DS (DS-AL) has been recognized for decades, consisting of an approximately 150-fold higher risk of …
IMPORTANCE: Down syndrome (DS), caused by an extra copy of material from chromosome 21, is one of the most common genetic conditions. The in …
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
Saygin C, Cannova J, Stock W, Muffly L. Saygin C, et al. Haematologica. 2022 Dec 1;107(12):2783-2793. doi: 10.3324/haematol.2022.280638. Haematologica. 2022. PMID: 36453516 Free PMC article.
Measurable residual disease (MRD) is the most powerful independent predictor of risk of relapse and long-term survival in adults and children with acute lymphoblastic leukemia (ALL). ...Several new immunotherapy approaches including blinatumomab, inotuzumab o …
Measurable residual disease (MRD) is the most powerful independent predictor of risk of relapse and long-term survival in adults and …
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, Faul C, Brüggemann M, Taylor K, Mergen N, Reichle A, Horst HA, Havelange V, Topp MS, Bargou RC. Gökbuget N, et al. Leuk Lymphoma. 2020 Nov;61(11):2665-2673. doi: 10.1080/10428194.2020.1780583. Epub 2020 Jul 3. Leuk Lymphoma. 2020. PMID: 32619115
Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). ...
Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic …
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Golub TR, et al. Science. 1999 Oct 15;286(5439):531-7. doi: 10.1126/science.286.5439.531. Science. 1999. PMID: 10521349
A class discovery procedure automatically discovered the distinction between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) without previous knowledge of these classes. An automatically derived class predictor was able to determine …
A class discovery procedure automatically discovered the distinction between acute myeloid leukemia (AML) and acute lymphoblastic …
Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis.
Zhang Y, Wang S, Zhang J, Liu C, Li X, Guo W, Duan Y, Chen X, Zong S, Zheng J, Wu Y, Chen X, Cheng X, Chang Y, Wang Y, Ding F, Yang W, Chen X, Guo Y, Zhang L, Chen Y, Zou Y, Zhu X, Gu J, Cheng T. Zhang Y, et al. Nat Cell Biol. 2022 Feb;24(2):242-252. doi: 10.1038/s41556-021-00814-7. Epub 2022 Feb 10. Nat Cell Biol. 2022. PMID: 35145224
Unfortunately, our understanding of the resistance elicited in minimal residual disease is limited due to the rarity and heterogeneity of the residual cells. Here we generated 161,986 single-cell transcriptomes to analyse the dynamic changes of B-cell acute lymph …
Unfortunately, our understanding of the resistance elicited in minimal residual disease is limited due to the rarity and heterogeneity of th …
7,226 results